REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...

Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond better to dual ANG2/VEGF-A inhibition than VEGF monotherapy. Faricimab ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and str ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months ; Early signal ...

2 Development Division, CHA Biotech Company, Ltd, Seoul, Republic of Korea 3 Division of Rheumatology, Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea 4 ...

When even the most highly trained surgeons perform procedures on the retina—one of the smallest, most delicate parts of the human body—the stakes are high. Surgeons must account for patients’ ...

For many ocular diseases, gene expression control by gene augmentation or gene inhibition strategies are revolutionizing the field of ocular drug delivery by proposing compounds with long term effects ...

DURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...

DURHAM, N.C., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...